SBBP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs...

Stats
今日成交量	684 683
平均成交量	316 352
市值	0.00
EPS	$-0.0700 ( 2021-08-05 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.111 (5.55%)

Insider Trading

Date	Person	Action	Amount	type
2021-10-05	Cdk Associates, L.l.c.	Sell	8 060 682	Ordinary Shares, $0.01 par value
2021-10-05	Cdk Associates, L.l.c.	Sell	2 220 000	Ordinary Shares Warrant (right to buy)
2021-10-05	Wilhoit Scott L.	Sell	109 510	Ordinary Shares
2021-10-05	Wilhoit Scott L.	Sell	649 000	Stock Option (Right to Buy)
2021-10-05	Kollender Richard S	Sell	234 229	Ordinary Shares

INSIDER POWER
0.00
Last 99 transactions
Buy: 6 188 774 \| Sell: 17 044 650

音量相关性

長: 0.22 (neutral)

短: -0.76 (moderate negative)

Signal:(42.06) Neutral

Strongbridge Biopharma 相关性

10 最正相关
ATNX	0.904
FINW	0.898
ORRF	0.896
RAPT	0.895
CFV	0.894
REKR	0.891
COMM	0.89
VIEW	0.889
GMII	0.889
SABR	0.888

10 最负相关
DFH	-0.93
COUP	-0.912
ICON	-0.91
PCTI	-0.903
CRVL	-0.902
FEYE	-0.9
CVT	-0.899
TWNK	-0.894
CFMS	-0.891
BTF	-0.889

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Strongbridge Biopharma 相关性 - 货币/商品

-0.12
( neutral )

-0.60
( weak negative )

0.00
( neutral )

0.01
( neutral )

0.38
( neutral )

0.81
( strong )

Strongbridge Biopharma 财务报表

Annual	2020
营收:	$30.73M
毛利润:	$28.52M (92.80 %)
EPS:	$-0.780

FY	2020
营收:	$30.73M
毛利润:	$28.52M (92.80 %)
EPS:	$-0.780

FY	2019
营收:	$21.71M
毛利润:	$17.89M (82.40 %)
EPS:	$-0.910

FY	2018
营收:	$18.03M
毛利润:	$14.04M (77.89 %)
EPS:	$0.690

Financial Reports:

No articles found.

Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.